中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
8期
1428-1429,1433
,共3页
甘露聚糖肽%序贯治疗%直肠癌%胸腺肽
甘露聚糖肽%序貫治療%直腸癌%胸腺肽
감로취당태%서관치료%직장암%흉선태
Mannatide%Sequential therapy%Rectal cancer%Thymosin
目的：观察甘露聚糖肽疗法与放射治疗、化学治疗(放化疗)联合应用治疗直肠癌的临床疗效。方法：将60例直肠癌患者随机平均分为试验组和对照组。两组均给予常规治疗--化疗CapeOX方案：奥沙利铂,130mg/m2,第一天；卡培他滨,850mg/m2,每日2次,持续14天；每3周为一周期,连用2个周期。试验组在常规治疗基础上接受甘露聚糖肽序贯治疗；对照组在常规治疗基础上接受胸腺肽序贯治疗。统计患者生存质量,测定免疫学指标以及记录不良反应。结果：治疗后试验组甘露聚糖肽能延长患者的中位生存期,显著提高治疗结束后1年的卡氏评分,与对照组相比有显著性差异(P<0.05)；免疫指标较治疗前均有所改善,试验组CD4/CD8(比值)较对照组具有显著性差异[(1.57±0.39)比(1.42±0.30),P<0.05],NK细胞、中性粒细胞水平亦有显著性差异(P=0.038和P=0.042)。结论：甘露聚糖肽序贯治疗与放化疗联合应用,治疗晚期直肠癌,可显著提高患者生存质量,全面增强患者免疫功能,减低放化疗带来的副作用,效果优于胸腺肽序贯治疗。
目的：觀察甘露聚糖肽療法與放射治療、化學治療(放化療)聯閤應用治療直腸癌的臨床療效。方法：將60例直腸癌患者隨機平均分為試驗組和對照組。兩組均給予常規治療--化療CapeOX方案：奧沙利鉑,130mg/m2,第一天；卡培他濱,850mg/m2,每日2次,持續14天；每3週為一週期,連用2箇週期。試驗組在常規治療基礎上接受甘露聚糖肽序貫治療；對照組在常規治療基礎上接受胸腺肽序貫治療。統計患者生存質量,測定免疫學指標以及記錄不良反應。結果：治療後試驗組甘露聚糖肽能延長患者的中位生存期,顯著提高治療結束後1年的卡氏評分,與對照組相比有顯著性差異(P<0.05)；免疫指標較治療前均有所改善,試驗組CD4/CD8(比值)較對照組具有顯著性差異[(1.57±0.39)比(1.42±0.30),P<0.05],NK細胞、中性粒細胞水平亦有顯著性差異(P=0.038和P=0.042)。結論：甘露聚糖肽序貫治療與放化療聯閤應用,治療晚期直腸癌,可顯著提高患者生存質量,全麵增彊患者免疫功能,減低放化療帶來的副作用,效果優于胸腺肽序貫治療。
목적：관찰감로취당태요법여방사치료、화학치료(방화료)연합응용치료직장암적림상료효。방법：장60례직장암환자수궤평균분위시험조화대조조。량조균급여상규치료--화료CapeOX방안：오사리박,130mg/m2,제일천；잡배타빈,850mg/m2,매일2차,지속14천；매3주위일주기,련용2개주기。시험조재상규치료기출상접수감로취당태서관치료；대조조재상규치료기출상접수흉선태서관치료。통계환자생존질량,측정면역학지표이급기록불량반응。결과：치료후시험조감로취당태능연장환자적중위생존기,현저제고치료결속후1년적잡씨평분,여대조조상비유현저성차이(P<0.05)；면역지표교치료전균유소개선,시험조CD4/CD8(비치)교대조조구유현저성차이[(1.57±0.39)비(1.42±0.30),P<0.05],NK세포、중성립세포수평역유현저성차이(P=0.038화P=0.042)。결론：감로취당태서관치료여방화료연합응용,치료만기직장암,가현저제고환자생존질량,전면증강환자면역공능,감저방화료대래적부작용,효과우우흉선태서관치료。
Objective:To observe the clinical efficacy of Mannatide sequential therapy combined with radiotherapy and chemotherapy to treat rectal cancer.Methods:60 patients with rectal cancer were randomly divided into experimental and control groups. The two groups were given conventional treatment-chemotherapy program of CapeOX:on the first day,use oxaliplatin 130mg/m2;and capecitabine 850mg/m2,2 times a day for 14 days;every 3 weeks for a cycle,and applied two cycles.The experimental group on the basis of conventional treatment accepted Mannatide sequential treatment;and the control group accepted thymosin sequential treatment control group accepted on the basis of conventional therapy.Count the patients’ quality of life, detect the immune indexes and record adverse reactions.Results:Mannatide can prolong median survival time of the experimental group and significantly improve Karnofsky score one year after the end of treatment.There is significant difference compared with the control group (P<0.05).Immune indexes were improved compared to that before treatment.There is significant difference between experiment group and control group with the CD4/CD8 (ratio) [(1.57±0.39) than (1.42±0.30),P<0.05);and the NK cells,neutrophils levels showed significant difference (P=0.038 and P=0.042). Conclusion:The method of Mannatide sequential treatment combined with radiotherapy and chemotherapy to treat rectal cancer can significantly improve the quality of life of patients,comprehensively enhance the immune function of patients,and reduce the side effects of radiotherapy and chemotherapy.The clinical effect of Mannatide sequential therapy is better than thymosin sequential therapy.
